Nesidioblastosis Associated with Pancreatic Heterotopia as a Differential Diagnosis of Hypoglycemia: A Literature Review and Case Report.

BACKGROUND Nesidioblastosis is a rare disease that is part of the differential diagnosis of pancreatogenic hyperinsulinemic hypoglycemia (PHH) in patients whose imaging studies do not localize insulinoma. Pancreatic heterotopia is a rare congenital abnormality characterized by pancreatic tissue anatomically separated from the main gland and found in 0.5% of abdominal surgeries.

Vascular effects of bisphosphonates-a systematic review.

Background: Osteoporosis and cardiovascular disease are interconnected entities with pathophysiological similarities. Bisphosphonates are therapeutic options available for resorptive bone diseases; however, experimental evidence has demonstrated a role for bisphosphonates in the inhibition of atherogenesis.

Methods: A systematic review of the vascular effects of bisphosphonates on atherosclerosis was performed.

Changes in HDL cholesterol and in the inflammatory markers of atherogenesis after an oral fat load in type-2 diabetic patients and normal individuals.

Background: Type-2 diabetic patients exhibit postprandial hypertriglyceridemia, a risk factor for atherosclerosis. Several inflammatory markers are also risk factors for atherosclerosis, such as ultrasensitive C-reactive protein (CRP) and number of leukocytes. There is a relationship between the increase in triglycerides and that of leukocytes in the postprandial period.

Differences in accuracy of 99mTc-sestamibi scanning between severe and mild forms of primary hyperparathyroidism.

Unlabelled: Preoperative localization of the parathyroids using (99m)Tc-sestamibi scanning has not yet been established as a routine diagnostic procedure for primary hyperparathyroidism. Several studies have demonstrated a variable degree of accuracy (70%-98%) in asymptomatic patients.

Methods: We evaluated the accuracy of this technique in 64 patients who underwent scanning between January 2000 and January 2005 according to the clinical manifestations of the disease.